drugset / Trial / NCT06555263
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1
Timeline
- Start
- 2024-08-21
- Primary completion
- 2025-05-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luveltamab tazevibulin | Monoclonal antibody | 4.3 mg/kg | Intravenous |
| Subject | Luveltamab tazevibulin | Monoclonal antibody | 5.2 mg/kg | Intravenous |